DSP builds partnership to commercialize iPS cell therapies
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has become the first pharma firm to take decisive steps towards the commercialization of therapies based on induced pluripotent stem (iPS) cells by signing agreements with a Japanese bioventure for regenerative treatments for age-related macular degeneration (AMD).